Exagen will pay Cypress up to $8 million in upfront and milestone payments as well as additional royalty payments for the business.
Under the deal, Marina will receive $750,000 up front, and stands to be paid as much as $27 million in milestones.
The firm offers its Avise PG test as a service for physicians making decisions about methotrexate therapy.
Cypress will pay up to $5 million for the technology, which it plans to use for diagnosis and therapeutic monitoring of lupus patients.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.